SCHEMBL25801608

SCHEMBL25801608

CC(C)C1CCC(C(=O)NCC[Si](C(C)C)(C(C)C)C(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 4/20 0.46
ROCK1 Q13464 4/20 0.46
LMNA P02545 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
HSD17B10 Q99714 2/20 0.38
NAAA Q02083 1/20 0.37
KMT2A Q03164 1/20 0.36
PSMB5 P28074 1/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MTNR1A P48039 2/20 0.35
MTNR1B P49286 2/20 0.35
GNAI3 P08754 1/20 0.35
GNAO1 P09471 1/20 0.35
GNAI1 P63096 1/20 0.35
PKN2 Q16513 3/20 0.35
RPS6KA5 O75582 2/20 0.35
LRRK2 Q5S007 2/20 0.35
TP53 P04637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25801595 0.91 ROCK2 (0.43) ROCK2ROCK1LMNATDP1HSD17B10
SCHEMBL25801602 0.85 ROCK2 (0.47) ROCK2ROCK1LMNATDP1HSD17B10
SCHEMBL10270570 0.81 ROCK2 (0.45) ROCK2ROCK1LMNATDP1HSD17B10
SCHEMBL25801607 0.81 ROCK2 (0.43) ROCK2ROCK1LMNATDP1HSD17B10
SCHEMBL22509724 0.80 HSD17B10 (0.57) ROCK2ROCK1LMNATDP1HSD17B10
SCHEMBL10270126 0.80 HSD17B10 (0.57) ROCK2ROCK1LMNATDP1HSD17B10
SCHEMBL25801740 0.79 NAAA (0.57) ROCK2ROCK1LMNANAAAKMT2A
SCHEMBL17132547 0.78 LMNA (0.49) ROCK2ROCK1LMNATDP1HSD17B10
SCHEMBL24202420 0.77 NAAA (0.64) NAAAALDH1A1GNAI3GNAO1GNAI1
SCHEMBL25801598 0.77 HSD17B10 (0.48) ROCK2ROCK1LMNATDP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11696959-B2 Nanoparticle-cell construct with platinum anti-cancer agent CITY OF HOPE (US) 2023-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11696959-B2 Nanoparticle-cell construct with platinum anti-cancer agent CD47, TP53, CD63 ROCK2 2310/4885ROCK1 1926/4885LMNA 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.